Home   中文简体 中文繁體 
Company News Products R&D Investor relationship Human Resource Contact Us
 
 
 
News
 
As Category 1 of Therapeutic Biological Product, “Recombinant Anti-CD30 Human-mouse Chimeric Monoclonal” has achieved Clinical Trial Permission with approval number of 2018L02789   2018-07-20 10:30
        As Category 1 of Therapeutic Biological Product, “Recombinant Anti-CD30 Human-mouse Chimeric Monoclonal” has achieved Clinical Trial Permission with approval number of 2018L02789。 

Links  |  SiteMap  |  Privacy Copyright© Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Ltd. 2007
(沪)-非经营性-2019-0143    沪ICP备10027510号-1